Nakaya Takeo

ナカヤタケオ | Nakaya Takeo

Affiliation and department：
Homepage URL (1)： https://kaken.nii.ac.jp/d/r/80512277.ja.html

Research field (4)： Experimental pathology , Tumor biology , Pharmaceuticals - chemistry and drug development , Human pathology

Research keywords (13)：がん分子創薬 , 創薬病理学 , 大腸癌 , 蛋白間相互作用阻害薬 , 病理診断学 , New Cancer Therapy , Stem cell , 腫瘍抑制 , がん , KLF5 , EBウイルス , 癌幹細胞 , LMP2A

Research theme for competitive and other funds (11)：

2023 - 2026 Elucidation of the mechanism of myocardial energy metabolism regulation by NC compound, a KLF5 inhibitor with a beneficial effect on heart failure.
2020 - 2024 膵癌リンパ管侵襲の病態解明とそれを抑制する新規治療法の開発
2019 - 2023 癌を選択的に抑制しかつ心機能を改善するKLF5阻害薬の開発とその分子作用機序解明
2018 - 2021 Molecular mechanism of familial aortic dissection by smooth muscle myosin mutation and elucidation of vascular aging mechanism
2016 - 2020 Elucidation of the KLF protein complex in intestinal tissues and development of new drugs to suppress protein-protein interactions for the treatment of colorectal cancer

Show all

Papers (37)：

Kentaro Tsuji, Hirotoshi Kawata, Tomoko Kamiakito, Takeo Nakaya, Akira Tanaka. RNA-binding protein 14 promotes phase separation to sustain prostate specific antigen expression under androgen deprivation in human prostate cancer. The Journal of steroid biochemistry and molecular biology. 2023. 235. 106407-106407
Kiyokuni Tanabe, Kensuke Yokoyama, Atsushi Kanno, Eriko Ikeda, Kozue Ando, Hiroki Nagai, Takahiro Koyanagi, Mio Sakaguchi, Takeo Nakaya, Kiichi Tamada, et al. Immune Checkpoint Inhibitor-induced Pancreatitis with Pancreatic Enlargement Mimicking Autoimmune Pancreatitis: A Case Report and Review of the Literature. Internal medicine (Tokyo, Japan). 2023
Yuma Horii, Shoichi Matsuda, Chikashi Toyota, Takumi Morinaga, Takeo Nakaya, Soken Tsuchiya, Masaki Ohmuraya, Takanori Hironaka, Ryo Yoshiki, Kotaro Kasai, et al. VGLL3 is a mechanosensitive protein that promotes cardiac fibrosis through liquid-liquid phase separation. Nature Communications. 2023. 14. 1
仲矢丈雄, 相澤健一, 田口由起, 辻賢太郎, 關根沙知, 村上知弘, 近藤恭光, 旦慎吾, 吉森篤史, 小路弘行, et al. がん創薬の新しい潮流天然変性蛋白かつ核内因子であるがん関連転写因子KLF5を標的とした低分子化合物の開発(Development of low-molecular-weight compounds targeting the cancer-associated KLF5 transcription factor). 日本癌学会総会記事. 2022. 81回. S10-6
Hiroka Iwata, Koji Kamiya, Soichiro Kado, Takeo Nakaya, Hirotoshi Kawata, Mayumi Komine, Mamitaro Ohtsuki. Case of immunoglobulin A vasculitis following coronavirus disease 2019 vaccination. The Journal of dermatology. 2021. 48. 12. e598-e599

ｍore...

MISC (3)：

仲矢丈雄, 小川誠司, 眞鍋一郎, 田中正視, 眞田昌, 佐藤俊朗, 武藤誠, 中尾和貴, 深山正久, 黒田雅彦, et al. KLF5は、腸管幹細胞の正常性と発癌能の調節に重要な因子として機能する(KLF5 functions as the master regulator of the integrity and oncogenicity of intestinal stem cells). 日本病理学会会誌. 2013. 102. 1. 346-346
仲矢丈雄, 黒田雅彦, 大木忠明. 次世代に向けた核酸医薬品の新技術 : RNA干渉法を用いた分子標的核酸医薬の開発. 化学. 2012. 67. 9. 25-29
仲矢丈雄, 眞田昌, 眞鍋一郎, 深山正久, 小川誠司, 黒田雅彦, 永井良三. KLF5は腸管腫瘍形成に必須である(KLF5 is essential for oncogenesis of intestinal tumors). 日本癌学会総会記事. 2012. 71回. 443-444

Books (4)：

Precision Medicine
2018
化学
化学同人 2012
病理画像診断これでスッキリ!
メジカルビュー 2012
がんプロフェッショナル養成講座腫瘍病理学
文光堂 2008

Lectures and oral presentations (4)：

Small molecules mimicking KLF5 structure suppresses cancer cells in both in vivo and vitro without damaging normal cells.
(6th International Conference on Biology and Pathobiology of KLF/Sp Transcription Factors 2018)
Small mimicries of KLF5 selectively suppress the survival and Wnt-KLF5 signal of colorectal cancer.
(2017)
The protein interaction inhibitors of KLF5 suppress Wnt signal activation selectively in colorectal cancer cells.
(2016)
The protein interaction inhibitors of KLF5 suppress Wnt signal activation selectively in colorectal cancer cells.
(FASEB SRC, KLF and SP Transcription Factors In Disease And Regenerative Medicine 2016)

Professional career (1)：

博士(医学) (東京大学)

※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page